Aldolase A deficiency: Report of new cases and literature review

C. Papadopoulos, M. Svingou, K. Kekou, S. Vergnaud, S. Xiou, G. Niotakis, G. K. Papadimas

1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Greece
Laboratory of Medical Genetics, Medical School, National and Kapodistrian University of Athens, “Aghia Sophia” Children’s Hospital, Athens, Greece
Department of Biochemistry, Toxicology et Pharmacology, CHU de Grenoble, Centre de Référence Rhone-Alpes des Maladies NeuroMusculaires, Grenoble, France
Pediatric Neurology Clinics, Venizeleion General Hospital, Heraklion, Crete, Greece

ARTICLE INFO
Keywords:
Aldolase A
Rhabdomyolysis
Hemolytic anemia

ABSTRACT
Aldolase A (ALDOA), is the predominant isoform of aldolase in skeletal muscle and erythrocytes that catalyzes the reversible conversion of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate. Autosomal recessive mutations in ALDOA, are extremely rare and cause hemolytic anemia and/or recurrent episodes of rhabdomyolysis, usually precipitated by fever. In this report we describe clinical, laboratory and genetic data of two novel unrelated patients harboring mutations in the ALDOA gene who presented with episodic rhabdomyolysis, we review all previously published cases and discuss the most valuable features for diagnosis of this rare disorder.

1. Introduction
Fruuctose-biphosphate aldolase (Aldolase A, ALDOA), is the predominant isoform of aldolase in skeletal muscle and erythrocytes encoded by the ALDOA gene on chromosome 16. ALDOA is a glycolytic enzyme that catalyzes the reversible conversion of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate [1]. Autosomal recessive mutations in ALDOA, are extremely rare and were originally reported to cause hemolytic anemia by impairing thermostability of the enzyme [2–4]. Subsequent reports have identified ALDOA deficiency as a cause of recurrent episodes of rhabdomyolysis, usually precipitated by fever, not always associated with hemolytic anemia, designating the disease as glycogen storage disease type 12 (GSD12) [5–7]. In this report, we describe clinical, laboratory and genetic data of two unrelated novel patients harboring mutations in the ALDOA gene who presented with episodes of rhabdomyolysis. We also review all previously published cases and discuss the most valuable features for diagnosis of this rare disorder.

2. Patients and methods
We present clinical, laboratory and genetic data from two male unrelated Greek patients with ALDOA gene pathogenic variants.

2.1. Muscle biopsy and biochemical studies
Open quadriceps muscle biopsy was obtained from patient 1 and processed using conventional routine morphological techniques [8]. Aldolase A activity in skeletal muscle was determined as previously described [7].

2.2. Molecular studies
DNA was extracted from peripheral blood lymphocytes from patients 1 and 2 and their relatives. Genetic analysis was performed with semitargeted Exome Sequencing, using Sophia Genetics Clinical Exome Panel (CES) and Nextera Rapid Capture Exome (Illumina), running on a NextSeq-500 (Illumina USA). The CES panel includes ~4900 genes (114.405 exons), linked to known genetic disorders more than 500 of which are muscle associated Bioinformatic data analysis with SOPHIA DDM (Sophia Genetics) and VarAFT 2.14 was performed. Variants were classified according to the 2015 American College of Medical Genetics and Genomics (ACMG) criteria. In silico analysis of variants included evaluation with tools like PROVEAN, Mutation Taster, SIFT, and Polyphen-2. All results and variant segregation patterns were confirmed by Sanger sequencing when appropriate.

Abbreviations: Aldolase A, ALDOA; glycogen storage disease type, GSD; electromyography, EMG.
* Corresponding author at: Constantinos Papadopoulos; First Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Greece.
E-mail addresses: constantinospapadopoulos@yahoo.com (C. Papadopoulos), kkekou@med.uoa.gr (K. Kekou), svergnaud@chu-grenoble.fr (S. Vergnaud).

https://doi.org/10.1016/j.ymgmr.2021.100730
Received 22 December 2020; Received in revised form 3 February 2021; Accepted 3 February 2021
2214-4269/© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
3. Results

3.1. Clinical findings

Patient 1 is a 24-year-old male of Albanian origin. He was born at term after a normal pregnancy from a non-consanguineous marriage. There was no family history of a neuromuscular disease. His psychomotor development was marked by a language delay which was finally gained at the age of 8 years and growth retardation treated with growth hormone replacement for 8 years. The patient reported that, since the age of 8 years, he presented recurrent episodes of myalgia and dark urine, following long exercise or pyrexia, for which he had never sought medical opinion. Upon presentation, at the age of 23 years, he had mild lordosis and scapula alata, distal hand weakness (interossei graded 3/5 at the MRC scale bilaterally) and neck flexion weakness (3/5 at the MRC scale). Laboratory evaluation revealed high creatine kinase levels (CK, 1500 U/L, normal range 25–190 IU/L), chronic hemolytic anemia and persistently elevated ferritin levels. A forearm lactate test showed normal lactate and ammonia rise. Needle electromyography (EMG) demonstrated small amplitude, short duration, polyphasic motor unit action potentials, with early recruitment both on proximal and on distal upper and lower limb muscles. Nerve conduction studies were normal.

Patient 2 is a 5-year-old boy, born, from a non-consanguineous marriage, at 38 weeks of gestation by caesarian section. On the second day of life, he presented tachypnea and failure to thrive. He was admitted to the neonatal intensive care unit where clinical examination upon admission showed a poor general condition, with a weak cry and a low muscle tone. Laboratory evaluation at the episode, revealed rhabdomyolysis with high CK levels (59,670 U/L, normal range 25–190 IU/L), myoglobinuria, as well as high total bilirubin and ferritin levels. A thorough search for an underlying metabolic disease, including serum carnitine, plasma acylcarnitines, urine amino and organic acids averred negative. The patient was treated with intravenous hydration with subsequent improvement and was discharged a week later in a good general condition and a normal clinical examination. At the age of 2.5 years, and during the course of a viral infection with high fever, he presented a second episode of rhabdomyolysis with CK levels reaching 24,000 U/L, myoglobinuria, as well as high total bilirubin and ferritin levels. He was treated with hydration and was discharged 5 days later. Currently, on last examination, the patient has normal psychomotor development and presents no signs of neuromuscular disorder. His CK levels are moderately elevated (600, U/L, normal range 25–190 IU/L), he has no sign of chronic haemolytic anemia or hypeferritinemia.

The characteristics of all reported cases of ALDOA gene mutations associated with rhabdomyolysis and/or myopathy are summarized in Table 1.

3.2. Muscle biopsy and biochemical studies

An open deltoid muscle biopsy was performed on patient 1 at the age of 23 years. The biopsy showed non-specific myopathic findings including rare atrophic and regenerative fibers and increased number of central nuclei. ALDOA activity in frozen skeletal muscle was decreased (125 nmol/h/mg; normal 581–5188 nmol/h/mg). Western blot analysis performed on muscle biopsy of patient 1 showed almost complete absence of aldolase A protein compared to control sample (Fig. 1).

3.3. Genetic studies

Genetic analysis data identified two known pathogenic variants in the ALDOA gene in patients 1 and 2. Patient 1 was homozygous for the c.839C>T (chr16:30081190, NM_184041: exon 8, p.Ala280Val) missense mutation and the status of homozygosity was confirmed by segregation analysis of the variation in the patient’s family. Patient 2 carried the already reported pathogenic missense mutation c.1016G>A in ALDOA gene (chr16:30081454, NM_184041: exon 9, p.Cys339Tyr) in heterozygous state. The segregation pattern of the variation was confirmed in the patient and his parents. The homozygous state at the ALDOA locus was confirmed in the patient’s parents.

Table 1. Patients’ characteristics.

| Patients | Age (yrs) | Gender | Pathology | Other | Aldolase A activity in muscle (nmol/h/mg)** | EMG | Muscle biopsy | Aldolase A activity in forearm muscle (nmol/h/mg)** | CPK at rest (U/L) | EMG at rest (U/L) | Rhodamine staining | Mutation*** | Reference |
|----------|-----------|--------|-----------|--------|---------------------------------------------|-----|--------------|-----------------------------------------------|----------------|----------------|----------------|-------------|-----------|
| P1        | 23        | Male   | Rhabdomyolysis | 2 episodes | c.839C>T, (p.Ala280Val) | Normal variability of both type 1 and type 2 action potentials, with early recruitment both on proximal and on distal upper and lower limb muscles. | Normal | Diminished muscle mass, proximal muscle weakness, slightly delayed motor acquisition. | Normal | 1500 | 9.48 | Homozygous c.839C>T (p.Ala280Val) | This report |
| L1        | 0.5       | Male   | Newborn | Fever | c.619G>A, (p.Glu206Lys) | Diminished muscle mass, proximal muscle weakness, slightly delayed motor acquisition. | Normal | Diminished muscle mass, proximal muscle weakness, slightly delayed motor acquisition. | Normal | 125 | 9.48 | Homozygous c.619G>A (p.Glu206Lys) | This report |
| P2        | 5         | Male   | Newborn | Fever | c.1016G>A, (p.Cys339Tyr) | Diminished muscle mass, proximal muscle weakness, slightly delayed motor acquisition. | Normal | Diminished muscle mass, proximal muscle weakness, slightly delayed motor acquisition. | Normal | 1900 | 9.48 | Homozygous c.1016G>A (p.Cys339Tyr) | Kreuder et al. [5] |
| L2        | 4         | Male   | Newborn | Fever | c.910C>T, (p.Arg304*) | Diminished muscle mass, proximal muscle weakness, slightly delayed motor acquisition. | Normal | Diminished muscle mass, proximal muscle weakness, slightly delayed motor acquisition. | Normal | 125 | 9.48 | Homozygous c.910C>T (p.Arg304*) | Yao et al. [6] |
| L3,L4     | 2 months | Male   | Newborn | Fever | N.P. | Diminished muscle mass, proximal muscle weakness, slightly delayed motor acquisition. | Normal | Diminished muscle mass, proximal muscle weakness, slightly delayed motor acquisition. | Normal | 125 | 9.48 | Homozygous c.2580G>A (p.Ala861Val) | Mamoune et al. [7] |

*Severe myopathy, short stature, polyphasic motor unit action potentials, with early recruitment. "Normal values: 881–5188 nmol/h/mg; N.P. Not performed. **S*nmol/h/mg. ***The nomenclature was adapted according to NM_184041.5 transcript.
P1 harbored the previously reported missense c.839C>T (p.Ala280Val) mutation [6]. Both variants are absent from controls (1000G and gnomAD) and multiple lines of computational evidence such as PROVEAN, Mutation Taster, SIFT, Polyphen-2 support a deleterious effect on the protein.

4. Discussion

In this report we describe two novel patients harboring mutations in the ALDOA gene. The first patient (P1) presented with episodes of rhabdomyolysis following fever or exercise since childhood and the second patient (P2) episodes of rhabdomyolysis in the context of viral infection since birth. Biochemical studies in patient P1 disclosed reduced ALDOA activity in muscle. Genetic studies showed that patient P1 harbored the previously reported missense c.839C>T (p.Ala280Val) homozygous variation in the ALDOA gene [7]. While patient P2 was homozygous for the previously reported c.1016G>A (p.Cys339Tyr) missense mutation [6].

The characteristics of all previously reported GSD12 cases are summarized in Table 1. Patients usually present with episodes of rhabdomyolysis starting at the newborn period or early childhood, usually, precipitated by fever. Electromyographic studies are not useful in the diagnosis, since they can be normal or show a non-specific myopathic pattern. Creatine kinase levels range in between attacks from normal to up to very highly elevated and muscle biopsy is not contributing to the diagnosis as it, usually, reveals non-specific alterations. Biochemical studies in muscle, when performed, show diminished ALDOA activity. Most reported patients present hemolytic anemia during episodes or even between attacks, a fact that can narrow down the differential diagnosis, since hemolysis is only associated with aldolase A [5], phosphofructokinase [9] and of phosphoglycerate kinase deficiency [10]. The presence of hemolysis is explained by the low activity of ALDOA in erythrocytes. Patients L3, L4, L5, were reported not to have chronic hemolytic anemia and only presented episodes of rhabdomyolysis [7]. The authors postulated that this was due to greater residual enzyme activity observed in these patients compared to previously reported cases, to the fact that hematological investigations were not performed during episodes of decompensation, or to a selective resistance to thermostability in erythrocytes [7]. Nevertheless, patient P1 with the same homozygous mutation shows chronic hemolytic anemia not related to acute episodes. Although we didn’t measure ALDOA activity in erythrocytes in P1, it seems that the clinical expression of ALDOA deficiency is not exclusively related to mutation type or tissue specific thermostability and that, probably, other factors contribute to this variable disease expression. These, still unidentified, factors, collectively, could explain the fact that originally, ALDOA deficiency was only reported as a cause of nonspherocytic hemolytic anemia, not related with skeletal muscle symptoms [2–4]. Mental retardation has been reported in the original ALDOA patients [2]. Subsequently reported patients [5–7], as well as patient P1, also showed learning disabilities or delayed language acquisition. Since ALDOA is the aldolase isoform with the most abundant expression in the brain [11], it is not surprising that mutations in the ALDOA gene could possibly result in subtle cognitive dysfunction and that brain involvement can be a part of the GSD12 spectrum.

Patient’s P1 most usual precipitant of rhabdomyolysis episodes was exercise, unlike previously reported patients, who usually experienced rhabdomyolysis following febrile illness [5–7]. It has been shown that the c.839C>T mutation affects thermostability of the enzyme and that stimulation of patients’ myoblasts with TNFα and IL-1β further reduces ALDOA activity [7]. Exercise increases core body temperature [12], while it induces secretion of pro-inflammatory cytokines, including TNFα and IL-1β [13]. Probably, high core body temperature and secretion of pro-inflammatory cytokines during exercise, exacerbates ALDOA deficiency leading to exercise-induced rhabdomyolysis [7]. This phenomenon could explain the normal results in the forearm exercise test performed in our patient. During the short duration of a forearm exercise test, performed on ambient conditions, the body core temperature doesn’t increase high enough in order to affect the thermostability of the enzyme. It is possible that the residual, decreased, enzymatic activity is sufficient enough for a normal exercise test.

Fixed muscle weakness seems not to be a constant feature of ALDOA deficiency. Some patients show mild proximal weakness at a very young age [5,6], while others, have no signs of muscle weakness until childhood [7]. Upon examination at 23-years of age, patient P1 had distal upper limb weakness, head flexion weakness and showed bilateral scapular winging, while other patients, homozygous for the same, c.839C>T mutation (L3, L4, L5) had no muscle weakness at a younger age [7]. It is unclear if this clinical difference is due to still unidentified additional genes and non-genetic factors such as lifestyle, nutrition or, yet, unknown environmental modifiers, or if muscle weakness will develop later in the course of their disease.

Patient P2, at the age of 5, shows a rather benign disease course with only 2 episodes of rhabdomyolysis and no signs of muscle weakness at last examination. On the contrary patient L2, heterozygous for the same missense mutation, that modifies the structure of the enzyme in a temperature-sensitive fashion, presented proximal lower limb weakness since the age of 2 and a severe disease course leading to death at 54 months of age. He, additionally, harbored the c.931C>T mutation (L3, L4, L5) had no muscle weakness at a younger age [7]. It is unclear if this clinical difference is due to still unidentified additional genes and non-genetic factors such as lifestyle, nutrition or, yet, unknown environmental modifiers, or if muscle weakness will develop later in the course of their disease.

Patient’s P2, at the age of 5, shows a rather benign disease course with only 2 episodes of rhabdomyolysis and no signs of muscle weakness at last examination. On the contrary patient L2, heterozygous for the same missense mutation, that modifies the structure of the enzyme in a temperature-sensitive fashion, presented proximal lower limb weakness since the age of 2 and a severe disease course leading to death at 54 months of age. He, additionally, harbored the c.931C>T mutation (L3, L4, L5) had no muscle weakness at a younger age [7]. It is unclear if this clinical difference is due to still unidentified additional genes and non-genetic factors such as lifestyle, nutrition or, yet, unknown environmental modifiers, or if muscle weakness will develop later in the course of their disease.

5. Conclusion

Patients with ALDOA deficiency show a rather homogeneous phenotype that comprises episodes of rhabdomyolysis, starting at the newborn or early childhood period, precipitated by fever or exercise and associated either with hemolysis or learning disabilities, or both.
Although both muscle biopsy and EMG may show non-specific myopathic changes hemolysis and learning disabilities are key features that may aid in achieving the correct diagnosis.

Funding

This study was supported by grants from the Scientific Society for Rare Disease & Orphan Drugs.

Declaration of Competing Interest

None.

References

[1] A. Kukita, M.C. Yoshida, S. Fukushige, M. Sakakibara, K. Joh, T. Mukai, K. Hori, Molecular gene mapping of human aldolase A (ALDOA) gene to chromosome 16, Hum. Genet. 76 (1987) 20–26, https://doi.org/10.1007/BF00283044.

[2] E. Beutler, S. Scott, A. Bishop, N. Margolis, F. Matsumoto, W. Kuhl, Red cell aldolase deficiency and hemolytic anemia: a new syndrome, Trans. Assoc. Am. Phys. 86 (1973) 154–166.

[3] S. Miwa, H. Fujii, K. Tani, K. Takahashi, S. Takegawa, N. Fujinami, M. Sakurai, M. Kubo, Y. Tanimoto, T. Kato, N. Matsumoto, Two cases of red cell aldolase deficiency associated with hereditary hemolytic anemia in a Japanese family, Am. J. Hematol. 11 (4) (1981 Dec) 425–437, https://doi.org/10.1002/ajh.2830110412.

[4] H. Kishi, T. Mukai, A. Hirono, H. Fujii, S. Miwa, K. Hori, Human aldolase A deficiency associated with a hemolytic anemia: thermolabile aldolase due to a single base mutation, Proc Natl AcadSci U S A. 84 (23) (1987 Dec) 8623–8627, https://doi.org/10.1073/pnas.84.23.8623.

[5] J. Kreuder, A. Borkhardt, R. Repp, A. Pekrun, B. Götsche, U. Gottschalk, H. Reichmann, W. Schachenmayr, K. Schlegel, F. Lampert, Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A, N. Engl. J. Med. 334 (17) (1996 Apr 25) 1100–1104, https://doi.org/10.1056/NEJM199604253341705.

[6] D.C. Yao, D.R. Tolan, M.F. Murray, D.J. Harris, B.T. Darras, A. Geva, E.J. Neufeld, Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDOA (Arg303X/Cys338Fyr), Blood 103 (6) (2004 Mar 15) 2401–2403, https://doi.org/10.1182/blood-2003-09-3160.

[7] A. Mamounou, M. Bahaa, Y. Hamel, V. Serre, M. Pelioli, F. Habarou, M.A. Nguyen Morel, B. Boison, S. Vergnaud, M.T. Vios, L. Nonnenmacher, M. Piraud, P. Nusbaum, J. Vamecq, N. Romero, C. Ottoleghi, J.L. Casanova, P. de Lonlay, A thermolabile aldolase A mutant causes fever-induced recurrent rhabdomyolysis without hemolytic anemia, PLoS Genet. 10 (11) (2014 Nov 13), e1004711, https://doi.org/10.1371/journal.pgen.1004711.

[8] V. Dubowitz, C. Sewry, A. Oldfors, Muscle Biopsy: A Practical Approach: Expert Consult, 4th ed, Saunders Ltd, 2013.

[9] J. Etiemble, A. Kahn, P. Boivin, J.F. Bernard, M. Goudemand, Hereditary hemolytic anemia with erythrocyte phosphofructokinase deficiency: studies of some properties of erythrocyte and muscle enzyme, Hum. Genet. 31 (1) (1976 Jan 28) 83–89, https://doi.org/10.1007/BF00270403.

[10] A. Echaniz-Laguna, Y. Nadjar, A. Behin, V. Biancalana, M. Piraud, E. Malfatti, P. Lafort, Phosphoglycerate kinase deficiency: a nationwide multicenter retrospective study, J. Inherit. Metab. Dis. 42 (5) (2019 Sep) 803–808, https://doi.org/10.1002/jimd.12087.

[11] P. Buono, F.P. D’Armiento, G. Terzi, A. Alfieri, F. Salvatore, Differential distribution of aldolase A and C in the human central nervous system, J. Neurocytol. 30 (12) (2001 Dec) 957–965, https://doi.org/10.1023/a:1021828421792.

[12] Institute of Medicine (US) Committee on Military Nutrition Research, Marriott BM, editor, Nutritional Needs in Hot Environments: Applications for Military Personnel in Field Operations, National Academies Press (US), Washington (DC), 1993, 3, Physiological Responses to Exercise in the Heat. Available from: https://www.ncbi.nlm.nih.gov/books/NBK823624/.

[13] B.K. Pedersen, Special feature for the Olympics: effects of exercise on the immune system: exercise and cytokines, Immunol. Cell Biol. 78 (5) (2000 Oct) 532–535, https://doi.org/10.1111/j.1440-1711.2000.001-11.x.